CA2878344A1 - Complexes of cytomegalovirus proteins - Google Patents
Complexes of cytomegalovirus proteins Download PDFInfo
- Publication number
- CA2878344A1 CA2878344A1 CA2878344A CA2878344A CA2878344A1 CA 2878344 A1 CA2878344 A1 CA 2878344A1 CA 2878344 A CA2878344 A CA 2878344A CA 2878344 A CA2878344 A CA 2878344A CA 2878344 A1 CA2878344 A1 CA 2878344A1
- Authority
- CA
- Canada
- Prior art keywords
- hcmv
- seq
- membrane protein
- complex
- protein complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108700010903 cytomegalovirus proteins Proteins 0.000 title description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims abstract description 289
- 102000018697 Membrane Proteins Human genes 0.000 claims abstract description 104
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract description 104
- 238000000034 method Methods 0.000 claims abstract description 99
- 239000000203 mixture Substances 0.000 claims abstract description 84
- 230000008569 process Effects 0.000 claims abstract description 63
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 57
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 57
- 229960005486 vaccine Drugs 0.000 claims abstract description 44
- 230000002163 immunogen Effects 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 224
- 102000004169 proteins and genes Human genes 0.000 claims description 204
- 235000018102 proteins Nutrition 0.000 claims description 200
- 210000004027 cell Anatomy 0.000 claims description 120
- 102000039446 nucleic acids Human genes 0.000 claims description 95
- 108020004707 nucleic acids Proteins 0.000 claims description 95
- 150000007523 nucleic acids Chemical class 0.000 claims description 95
- 230000014509 gene expression Effects 0.000 claims description 39
- 210000004962 mammalian cell Anatomy 0.000 claims description 21
- 239000012528 membrane Substances 0.000 claims description 21
- 210000002845 virion Anatomy 0.000 claims description 20
- 241000710929 Alphavirus Species 0.000 claims description 19
- 230000013595 glycosylation Effects 0.000 claims description 18
- 238000006206 glycosylation reaction Methods 0.000 claims description 18
- 241000238631 Hexapoda Species 0.000 claims description 15
- 230000003053 immunization Effects 0.000 claims description 15
- 238000002649 immunization Methods 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 13
- 239000001963 growth medium Substances 0.000 claims description 12
- 241000710188 Encephalomyocarditis virus Species 0.000 claims description 7
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 7
- 101710138767 Non-structural glycoprotein 4 Proteins 0.000 claims description 7
- 101710144127 Non-structural protein 1 Proteins 0.000 claims description 7
- 101710144128 Non-structural protein 2 Proteins 0.000 claims description 7
- 101710144111 Non-structural protein 3 Proteins 0.000 claims description 7
- 102100031776 SH2 domain-containing protein 3A Human genes 0.000 claims description 7
- 102100021798 SH2 domain-containing protein 3C Human genes 0.000 claims description 7
- 102100031056 Serine protease 57 Human genes 0.000 claims description 7
- 101710197596 Serine protease 57 Proteins 0.000 claims description 7
- 230000037452 priming Effects 0.000 claims description 7
- 210000003705 ribosome Anatomy 0.000 claims description 7
- 239000007764 o/w emulsion Substances 0.000 claims description 6
- 159000000013 aluminium salts Chemical class 0.000 claims description 4
- 235000004252 protein component Nutrition 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 229910000329 aluminium sulfate Inorganic materials 0.000 claims description 3
- 102100028253 Breast cancer anti-estrogen resistance protein 3 Human genes 0.000 claims 2
- 101150082158 UL128 gene Proteins 0.000 abstract description 6
- 101150088904 UL130 gene Proteins 0.000 abstract description 6
- 101100315698 Human cytomegalovirus (strain Merlin) UL131A gene Proteins 0.000 abstract description 5
- 239000000427 antigen Substances 0.000 description 59
- 102000036639 antigens Human genes 0.000 description 58
- 108091007433 antigens Proteins 0.000 description 58
- 108090000765 processed proteins & peptides Proteins 0.000 description 53
- 102000004196 processed proteins & peptides Human genes 0.000 description 48
- 229920001184 polypeptide Polymers 0.000 description 45
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 44
- 108010076504 Protein Sorting Signals Proteins 0.000 description 32
- 125000000539 amino acid group Chemical group 0.000 description 28
- 230000003472 neutralizing effect Effects 0.000 description 27
- 230000027455 binding Effects 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 24
- 239000000872 buffer Substances 0.000 description 23
- 241000272186 Falco columbarius Species 0.000 description 21
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 21
- 238000000746 purification Methods 0.000 description 19
- 230000004044 response Effects 0.000 description 19
- 210000004899 c-terminal region Anatomy 0.000 description 18
- 210000002919 epithelial cell Anatomy 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 241000701022 Cytomegalovirus Species 0.000 description 12
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- -1 cationic lipid Chemical class 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 238000001542 size-exclusion chromatography Methods 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 229920002873 Polyethylenimine Polymers 0.000 description 10
- 108010006025 bovine growth hormone Proteins 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 230000004988 N-glycosylation Effects 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 7
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000012124 Opti-MEM Substances 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000002823 phage display Methods 0.000 description 7
- 241000701447 unidentified baculovirus Species 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 108010087967 type I signal peptidase Proteins 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102100022648 Reticulon-2 Human genes 0.000 description 5
- 108091006629 SLC13A2 Proteins 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 238000011210 chromatographic step Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000007908 nanoemulsion Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010085220 Multiprotein Complexes Proteins 0.000 description 3
- 102000007474 Multiprotein Complexes Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000005101 cell tropism Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 101150068408 lnp1 gene Proteins 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000010187 selection method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000002090 Fibronectin type III Human genes 0.000 description 2
- 108050009401 Fibronectin type III Proteins 0.000 description 2
- 241000700586 Herpesviridae Species 0.000 description 2
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 108010015268 Integration Host Factors Proteins 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 101710186352 Probable membrane antigen 3 Proteins 0.000 description 2
- 101710181078 Probable membrane antigen 75 Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710178472 Tegument protein Proteins 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 2
- 241001504505 Troglodytes troglodytes Species 0.000 description 2
- 101150049363 UL131A gene Proteins 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 101150055782 gH gene Proteins 0.000 description 2
- 101150015940 gL gene Proteins 0.000 description 2
- 150000004676 glycans Chemical group 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 210000000688 human artificial chromosome Anatomy 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 239000000277 virosome Substances 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Polymers C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 241000701021 Betaherpesvirinae Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101150059079 EBNA1 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 239000012739 FreeStyle 293 Expression medium Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 101900312118 Human cytomegalovirus Envelope glycoprotein H Proteins 0.000 description 1
- 101900039244 Human cytomegalovirus Envelope glycoprotein UL130 Proteins 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 206010073371 Mucoepidermoid carcinoma of salivary gland Diseases 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101150081415 UL55 gene Proteins 0.000 description 1
- 101150060468 UL74 gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 108010038083 amyloid fibril protein AS-SAM Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 101150029683 gB gene Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000024697 human cytomegalovirus infection Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000005959 oncogenic signaling Effects 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108010052044 polyclonal B cell activator Proteins 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 208000012049 salivary gland mucoepidermoid carcinoma Diseases 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 238000012448 transchromosomic mouse model Methods 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668975P | 2012-07-06 | 2012-07-06 | |
| US61/668,975 | 2012-07-06 | ||
| US201361770257P | 2013-02-27 | 2013-02-27 | |
| US61/770,257 | 2013-02-27 | ||
| PCT/EP2013/063750 WO2014005959A1 (en) | 2012-07-06 | 2013-06-29 | Complexes of cytomegalovirus proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2878344A1 true CA2878344A1 (en) | 2014-01-09 |
Family
ID=48783208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2878344A Abandoned CA2878344A1 (en) | 2012-07-06 | 2013-06-29 | Complexes of cytomegalovirus proteins |
Country Status (17)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014KN02929A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2012-07-06 | 2015-05-08 | Novartis Ag | |
| ES2719720T3 (es) | 2012-07-27 | 2019-07-12 | Hope City | Una vacuna de MVA para la administración de un complejo de UL128 y para prevenir la infección por CMV |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| PL3077519T3 (pl) * | 2013-12-03 | 2021-10-18 | Hookipa Biotech Gmbh | Szczepionki CMV |
| EP3134117A1 (en) * | 2014-04-23 | 2017-03-01 | Institute for Research in Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| WO2015165480A1 (en) * | 2014-04-30 | 2015-11-05 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| SG11201608977UA (en) * | 2014-05-08 | 2016-11-29 | Pfizer | Means and methods for treating cmv |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| EP3047856A1 (en) * | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
| WO2017044895A2 (en) | 2015-09-10 | 2017-03-16 | City Of Hope | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| JP2019511255A (ja) | 2016-01-11 | 2019-04-25 | バーンダリ，インク． | マイクロニードル組成物およびそれを使用する方法 |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| JP2020515522A (ja) * | 2017-01-27 | 2020-05-28 | ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | 免疫応答を誘導するヘルペスウイルスエンベロープタンパク質の組み合わせのワクチン組成物 |
| EP4559869A3 (en) | 2017-04-04 | 2025-08-20 | University of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
| MX2019012525A (es) | 2017-04-19 | 2019-12-05 | Glaxosmithkline Biologicals Sa | Proteinas de citomegalovirus modificadas y complejos estabilizados. |
| US11174322B2 (en) * | 2017-07-24 | 2021-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies and peptides to treat HCMV related diseases |
| SG11202000019RA (en) * | 2017-07-28 | 2020-02-27 | Janssen Vaccines & Prevention Bv | Methods and compositions for heterologous reprna immunizations |
| EP3681534A1 (en) * | 2017-09-13 | 2020-07-22 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
| CA3095216A1 (en) * | 2018-02-28 | 2019-09-06 | University Of Washington | Self-asssembling nanostructure vaccines |
| JP7575096B2 (ja) | 2018-05-04 | 2024-10-29 | スパイバイオテック・リミテッド | ワクチン組成物 |
| CA3116175A1 (en) * | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| KR102609106B1 (ko) | 2018-12-10 | 2023-12-05 | 케이엠 바이올로직스 가부시키가이샤 | 사이토메갈로바이러스의 선천성 감염을 예방 또는 치료하기 위한 백신 |
| US11629172B2 (en) * | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| WO2021014385A1 (en) | 2019-07-24 | 2021-01-28 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
| JP7271794B2 (ja) * | 2020-06-09 | 2023-05-11 | Ｋｍバイオロジクス株式会社 | サイトメガロウイルスのｇＢとペンタマーとの融合タンパク質及び該融合タンパク質を含むワクチン |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US20230398211A1 (en) | 2020-10-28 | 2023-12-14 | Sanofi Pasteur | Liposomes Containing TLR4 Agonist, Preparation and Uses Thereof |
| CA3211449A1 (en) * | 2021-02-24 | 2022-09-01 | Pfizer Inc. | Novel druggable regions in the human cytomegalovirus glycoprotein b polypeptide and methods of use thereof |
| WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2176174T3 (es) | 1988-12-22 | 2002-12-01 | Genentech Inc | Procedimiento de preparacion de polipeptidos solubles en agua. |
| WO1990011361A1 (en) | 1989-03-17 | 1990-10-04 | E.I. Du Pont De Nemours And Company | External regulation of gene expression |
| JPH06501845A (ja) | 1990-08-02 | 1994-03-03 | カイロン コーポレイション | バキュロウイルス―昆虫細胞発現システムを用いたヒトｃｍｖ糖タンパク質―ｈの発現 |
| US5474914A (en) * | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
| US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| US5815900A (en) | 1995-03-06 | 1998-10-06 | Matsushita Electric Industrial Co., Ltd. | Method of manufacturing a surface acoustic wave module |
| WO2004076645A2 (en) * | 2003-02-27 | 2004-09-10 | University Of Massachusetts | Compositions and methods for cytomegalovirus treatment |
| EP3031469B1 (en) * | 2006-06-07 | 2023-08-23 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| US7947274B2 (en) * | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
| US9439960B2 (en) | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
| AU2010290896B2 (en) | 2009-09-02 | 2014-07-03 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions including TLR activity modulators |
| US9089537B2 (en) * | 2010-02-26 | 2015-07-28 | The Trustees Of The University Of Pennslyvania | Subunit vaccines for herpes viruses and methods of use |
| MX343410B (es) | 2010-07-06 | 2016-11-04 | Novartis Ag * | Emulsiones cationicas de agua en aceite. |
| SI2590626T1 (sl) | 2010-07-06 | 2016-01-29 | Glaxosmithkline Biologicals S.A. | Liposomi z lipidi, ki imajo koristno pKa vrednost, za dostavo RNA |
| WO2012015211A2 (ko) | 2010-07-30 | 2012-02-02 | 주식회사종근당 | 사이클로스포린 에이 함유 점안제 조성물 |
| EP2614072A4 (en) * | 2010-09-09 | 2014-03-19 | Univ Virginia Commonwealth | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| EP2627351B1 (en) * | 2010-10-11 | 2018-12-26 | GlaxoSmithKline Biologicals SA | Antigen delivery platforms |
| EP2670443A4 (en) | 2011-01-31 | 2015-10-14 | Univ Pennsylvania | FOR NUCLEIC ACID MOLECULAR ENCODING NEW HERPES ANTIGENES, VACCINES THEREOF AND METHOD OF USE THEREOF |
| RU2649133C2 (ru) | 2011-07-06 | 2018-03-29 | Новартис Аг | Катионные эмульсии масло-в-воде |
| EP2729168A2 (en) | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
| JP2014525461A (ja) * | 2011-08-31 | 2014-09-29 | ノバルティス アーゲー | 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム |
| IN2014KN02929A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2012-07-06 | 2015-05-08 | Novartis Ag | |
| EP3015475A1 (en) | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
-
2013
- 2013-06-29 IN IN2929KON2014 patent/IN2014KN02929A/en unknown
- 2013-06-29 GB GB1413863.0A patent/GB2513768B/en active Active
- 2013-06-29 AU AU2013286093A patent/AU2013286093B2/en not_active Ceased
- 2013-06-29 US US14/410,461 patent/US9683022B2/en active Active
- 2013-06-29 SG SG11201408328VA patent/SG11201408328VA/en unknown
- 2013-06-29 MX MX2014015496A patent/MX355469B/es active IP Right Grant
- 2013-06-29 CA CA2878344A patent/CA2878344A1/en not_active Abandoned
- 2013-06-29 WO PCT/EP2013/063750 patent/WO2014005959A1/en active Application Filing
- 2013-06-29 MX MX2018000675A patent/MX378747B/es unknown
- 2013-06-29 CN CN201380036145.0A patent/CN104853771A/zh active Pending
- 2013-06-29 KR KR1020157002267A patent/KR20150031322A/ko not_active Withdrawn
- 2013-06-29 HK HK15110880.5A patent/HK1210037A1/xx unknown
- 2013-06-29 EP EP13736518.5A patent/EP2869843B1/en active Active
- 2013-06-29 ES ES13736518T patent/ES2753138T3/es active Active
- 2013-06-29 RU RU2015103891A patent/RU2015103891A/ru not_active Application Discontinuation
- 2013-06-29 JP JP2015519155A patent/JP2015522581A/ja active Pending
-
2014
- 2014-12-15 IL IL236261A patent/IL236261A0/en unknown
- 2014-12-18 ZA ZA2014/09364A patent/ZA201409364B/en unknown
-
2017
- 2017-05-16 US US15/596,066 patent/US10287322B2/en active Active
- 2017-08-01 JP JP2017149178A patent/JP2017192399A/ja active Pending
- 2017-08-01 JP JP2017149179A patent/JP2017192400A/ja active Pending
-
2019
- 2019-03-25 US US16/363,127 patent/US20190211064A1/en not_active Abandoned
-
2021
- 2021-12-15 US US17/551,867 patent/US20220106364A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014015496A (es) | 2015-03-06 |
| KR20150031322A (ko) | 2015-03-23 |
| US10287322B2 (en) | 2019-05-14 |
| US20190211064A1 (en) | 2019-07-11 |
| IN2014KN02929A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-05-08 |
| IL236261A0 (en) | 2015-02-26 |
| HK1210037A1 (en) | 2016-04-15 |
| EP2869843B1 (en) | 2019-08-07 |
| MX355469B (es) | 2018-04-19 |
| ZA201409364B (en) | 2017-08-30 |
| AU2013286093B2 (en) | 2018-01-04 |
| SG11201408328VA (en) | 2015-02-27 |
| US20170320916A1 (en) | 2017-11-09 |
| US9683022B2 (en) | 2017-06-20 |
| GB2513768B (en) | 2015-04-15 |
| CN104853771A (zh) | 2015-08-19 |
| MX378747B (es) | 2025-03-10 |
| JP2017192400A (ja) | 2017-10-26 |
| AU2013286093A1 (en) | 2015-02-12 |
| US20220106364A1 (en) | 2022-04-07 |
| GB201413863D0 (en) | 2014-09-17 |
| JP2015522581A (ja) | 2015-08-06 |
| EP2869843A1 (en) | 2015-05-13 |
| ES2753138T3 (es) | 2020-04-07 |
| US20160159864A1 (en) | 2016-06-09 |
| RU2015103891A (ru) | 2016-08-27 |
| JP2017192399A (ja) | 2017-10-26 |
| GB2513768A (en) | 2014-11-05 |
| WO2014005959A1 (en) | 2014-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220106364A1 (en) | Complexes of cytomegalovirus proteins | |
| KR102242990B1 (ko) | 헤테로다이머 면역글로불린 구조체 및 이의 제조 방법 | |
| US20190307879A1 (en) | Adenovirus-vectored multivalent vaccine | |
| Zhao et al. | Immunization with Fc-based recombinant Epstein–Barr virus gp350 elicits potent neutralizing humoral immune response in a BALB/c mice model | |
| CN108373504A (zh) | Cd24特异性抗体和抗cd24-car-t细胞 | |
| CN114907457B (zh) | 一种寨卡/登革疫苗及其应用 | |
| US20170158753A1 (en) | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species | |
| US20170119874A1 (en) | Human cytomegalovirus vaccine compositions and method of producing the same | |
| CN112739359A (zh) | Apmv及其用于治疗癌症的用途 | |
| CN119119211A (zh) | 一种融合前构象的呼吸道合胞病毒重组融合蛋白、其制备方法及用途 | |
| CN118812669A (zh) | 呼吸道合胞病毒融合f蛋白突变体及其应用 | |
| US20230398201A1 (en) | Gene shuffled lyssavirus vaccine | |
| CN118406159B (zh) | RSV pre-F截短体及其生产方法和应用 | |
| JP6538151B2 (ja) | 抗ｃ型肝炎抗体及びその抗原結合断片 | |
| US20240287166A1 (en) | Dna antibody constructs for use against plasmodium parasites | |
| WO2024153068A1 (en) | Anti-pdl1 single domain antibody, fusion protein and use thereof | |
| US20240239875A1 (en) | Sars-cov-2 spike protein antibodies | |
| WO2018071345A1 (en) | Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop | |
| CN119708170A (zh) | RSV pre-F突变体及其制备方法和应用 | |
| Wang et al. | Research on the Construction Method and Characterization of Neutralizing Mouse-Canine Chimeric Antibody against Canine Distemper Virus | |
| CN118434766A (zh) | 双功能抗原结合分子 | |
| WO2025146159A1 (zh) | 针对寨卡/登革病毒的重组抗原、其疫苗组合物及其应用 | |
| CN115772544A (zh) | 抗vegf-a和ang-2的aav载体 | |
| HK40004712B (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
| HK40004712A (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20190702 |